source
- Genentech signs $1.5 billion bispecific antibody deal with Earendil LabsGenentech, Roche's US subsidiary, announced a licensing agreement with Earendil Labs to discover and develop multiple bispecific antibodies aimed at oncology. The agreement provides a $55 million…
- Boehringer Ingelheim partners with Envisagenics on $1 billion AI-driven oncology collaborationBoehringer Ingelheim and AI drug discovery firm Envisagenics have signed a potential $1 billion multi‑year agreement to validate tumor‑specific targets. The deal will see Boehringer use Envisagenic…